Common Contracts

5 similar Underwriting Agreement contracts by Laboratory Corp of America Holdings

Laboratory Corporation of America Holdings $600,000,000 3.250% Senior Notes Due 2024 $600,000,000 3.600% Senior Notes Due 2027 Underwriting Agreement
Underwriting Agreement • August 22nd, 2017 • Laboratory Corp of America Holdings • Services-medical laboratories • New York

Laboratory Corporation of America Holdings, a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (“you” or the “Representatives”) are acting as representatives, the principal amount of its notes identified in Schedule I hereto (the “Notes”), to be issued under an indenture dated as of November 19, 2010 as supplemented by the Eleventh Supplemental Indenture to be dated August 22, 2017 and the Twelfth Supplemental Indenture to be dated August 22, 2017 (collectively, the “Indenture”), each between the Company and U.S. Bank National Association, as trustee (the “Trustee”). To the extent there are no additional Underwriters named in Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires. Any reference herein to the

AutoNDA by SimpleDocs
Laboratory Corporation of America Holdings $500,000,000 2.625% Senior Notes Due 2020 $500,000,000 3.200% Senior Notes Due 2022 $1,000,000,000 3.600% Senior Notes Due 2025 $900,000,000 4.700% Senior Notes Due 2045 Underwriting Agreement
Underwriting Agreement • January 30th, 2015 • Laboratory Corp of America Holdings • Services-medical laboratories • New York

Laboratory Corporation of America Holdings, a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (“you” or the “Representatives”) are acting as representatives, the principal amount of its notes identified in Schedule I hereto (the “Notes”), to be issued under an indenture dated as of November 19, 2010 as supplemented by the Seventh Supplemental Indenture to be dated January 30, 2015, the Eighth Supplemental Indenture to be dated January 30, 2015, the Ninth Supplemental Indenture to be dated January 30, 2015 and the Tenth Supplemental Indenture to be dated January 30, 2015 (collectively, the “Indenture”), each between the Company and U.S. Bank National Association, as trustee (the “Trustee”). To the extent there are no additional Underwriters named in Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms

Laboratory Corporation of America Holdings $400,000,000 2.50% Senior Notes Due 2018 $300,000,000 4.00% Senior Notes Due 2023 Underwriting Agreement
Underwriting Agreement • November 1st, 2013 • Laboratory Corp of America Holdings • Services-medical laboratories • New York

Laboratory Corporation of America Holdings, a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (“you” or the “Representatives”) are acting as representatives, the principal amount of its notes identified in Schedule I hereto (the “Notes”), to be issued under an indenture dated as of November 19, 2010 as supplemented by the Fifth Supplemental Indenture and the Sixth Supplemental Indenture to be dated November 1, 2013 (collectively, the “Indenture”), each between the Company and U.S. Bank National Association, as trustee (the “Trustee”). To the extent there are no additional Underwriters named in Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires. Any reference herein to the Registration Statement, the Bas

Laboratory Corporation of America Holdings $500,000,000 2.20% Senior Notes Due 2017 $500,000,000 3.75% Senior Notes Due 2022 Underwriting Agreement
Underwriting Agreement • August 23rd, 2012 • Laboratory Corp of America Holdings • Services-medical laboratories • New York

Laboratory Corporation of America Holdings, a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the principal amount of its notes identified in Schedule I hereto (the “Notes”), to be issued under an indenture dated as of November 19, 2010 as supplemented by the Third Supplemental Indenture and the Fourth Supplemental Indenture to be dated August 23, 2012 (collectively, the “Indenture”), each between the Company and U.S. Bank National Association, as trustee (the “Trustee”). To the extent there are no additional Underwriters named in Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires. Any reference herein to the Registration Statement, the Base Prospec

Laboratory Corporation of America Holdings $325,000,000 3.125% Senior Notes Due 2016 $600,000,000 4.625% Senior Notes Due 2020 Underwriting Agreement
Underwriting Agreement • November 19th, 2010 • Laboratory Corp of America Holdings • Services-medical laboratories • New York

Laboratory Corporation of America Holdings, a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representative”) are acting as representative, the principal amount of its notes identified in Schedule I hereto (the “Notes”), to be issued under an indenture (the “Indenture”) dated as of November 19, 2010, between the Company and U.S. Bank National Association, as trustee (the “Trustee”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representative as used herein shall mean you, as Underwriter, and the terms Representative and Underwriters shall mean either the singular or plural as the context requires. Any reference herein to the Registration Statement, the Base Prospectus, any Preliminary Prospectus or the Final Prospectus shall be deemed to refer to and include the documents incorporated by reference therei

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!